Meeting
2020 ASCO Virtual Scientific Program
Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study.
Authors
Alberto Cruz Bermudez
Instituto Investigacion Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Alberto Cruz Bermudez , Marta Casarrubios , Raquel Laza Briviesca , Belen Sierra-Rodero , Miguel Barquin , Atocha Romero , Fernando Franco , Virginia Calvo , Ernest Nadal , Amelia Insa , Rosario Garcia-Campelo , Joaquin Casal , Manuel Domine , Bartomeu Massuti , Margarita Majem , Delvys Rodriguez-Abreu , Alex Martinez-Marti , Javier De Castro , Mariano Provencio-Pulla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03081689
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9041)
DOI
10.1200/JCO.2020.38.15_suppl.9041
Abstract #
9041
Poster Bd #
234
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.
First Author: Mariano Provencio
Poster
2018 ASCO Annual Meeting
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
First Author: Mariano Provencio-Pulla
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
First Author: Samuel Rosner